HK Stock Market Move | HBM Holdings-B (02142) rose nearly 6% in the afternoon, with the company continuing to buy back shares throughout the year. The total amount of share buybacks is approximately 1.3 billion Hong Kong dollars.

HBM HOLDINGS-B(02142) rose nearly 6% in the afternoon, as of the time of reporting, it rose by 4.9% to HK$8.14, with a turnover of HK$83.1892 million. On the news front, HepBio announced that, based on a stock repurchase plan totaling 240 million yuan, the company, considering that the current trading price levels undervalue the intrinsic value, business prospects, or recent business results, spent nearly 9 million yuan on repurchases in the open market on June 17. Since January 1 of this year, a total of 20.343 million shares worth approximately 130 million yuan have been repurchased. Between 2023 and 2024, the company has repurchased and canceled 5.87 million shares. In addition, HepBio recently announced that its wholly-owned subsidiary Nona Bioscience has entered into an authorization agreement with Visterra to utilize Nona Bioscience's proprietary only heavy chain antibody (HCAb) Harbour Mice technology platform to advance Visterra's next-generation immunomodulatory and autoimmune disease biological therapy pipeline. Nona Bioscience's HCAb Harbour Mice platform can generate fully human heavy chain antibodies, with major advantages such as reduced immunogenicity and increased potency of next-generation biological therapies. This innovative platform has been clinically validated and has been widely recognized by global partners.